The role of glucagon-like peptide-1 impairment in obesity and potential therapeutic implications
出版年份 2013 全文链接
标题
The role of glucagon-like peptide-1 impairment in obesity and potential therapeutic implications
作者
关键词
-
出版物
DIABETES OBESITY & METABOLISM
Volume 16, Issue 1, Pages 9-21
出版商
Wiley
发表日期
2013-04-25
DOI
10.1111/dom.12119
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Mechanisms and Clinical Efficacy of Lixisenatide for the Management of Type 2 Diabetes
- (2013) Michael Horowitz et al. ADVANCES IN THERAPY
- Effects of leptin replacement alone and with exendin-4 on food intake and weight regain in weight-reduced diet-induced obese rats
- (2012) Roger Reidelberger et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- Alterations in energy balance following exenatide administration
- (2012) David P. Bradley et al. Applied Physiology Nutrition and Metabolism
- Efficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors: Meta-Analysis and Systematic Review
- (2012) Vanita R. Aroda et al. CLINICAL THERAPEUTICS
- Outstanding Scientific Achievement Award Lecture 2011: Defeating Diabesity: The Case for Personalized Combinatorial Therapies
- (2012) M. H. Tschop et al. DIABETES
- Impairment of GLP1-induced insulin secretion: role of genetic background, insulin resistance and hyperglycaemia
- (2012) S. Herzberg-Schäfer et al. DIABETES OBESITY & METABOLISM
- Patient-reported outcomes in trials of incretin-based therapies in patients with type 2 diabetes mellitus
- (2012) M. Davies et al. DIABETES OBESITY & METABOLISM
- Liraglutide: short-lived effect on gastric emptying-long lasting effects on body weight
- (2012) J. Jelsing et al. DIABETES OBESITY & METABOLISM
- Monotherapy with the once-weekly GLP-1 analogue dulaglutide for 12 weeks in patients with Type 2 diabetes: dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled study
- (2012) G. Grunberger et al. DIABETIC MEDICINE
- Mechanisms of improved glycaemic control after Roux-en-Y gastric bypass
- (2012) C. Dirksen et al. DIABETOLOGIA
- Anti-obesity drugs: a review about their effects and their safety
- (2012) Giuseppe Derosa et al. Expert Opinion On Drug Safety
- The effect of a very low calorie diet on insulin sensitivity, beta cell function, insulin clearance, incretin hormone secretion, androgen levels and body composition in obese young women
- (2012) Pernille F. Svendsen et al. SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION
- Rapid Tachyphylaxis of the Glucagon-Like Peptide 1-Induced Deceleration of Gastric Emptying in Humans
- (2011) M. A. Nauck et al. DIABETES
- DPP-4 inhibitors in the management of type 2 diabetes: A critical review of head-to-head trials
- (2011) A.J. Scheen DIABETES & METABOLISM
- Short-Term Exenatide Treatment Leads to Significant Weight Loss in a Subset of Obese Women Without Diabetes
- (2011) J. Dushay et al. DIABETES CARE
- Efficacy and Safety of Exenatide Once Weekly Versus Metformin, Pioglitazone, and Sitagliptin Used as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4): A 26-week double-blind study
- (2011) D. Russell-Jones et al. DIABETES CARE
- Loss of Incretin Effect Is a Specific, Important, and Early Characteristic of Type 2 Diabetes
- (2011) J. J. Holst et al. DIABETES CARE
- An overview of once-weekly glucagon-like peptide-1 receptor agonists-available efficacy and safety data and perspectives for the future
- (2011) S. Madsbad et al. DIABETES OBESITY & METABOLISM
- Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity
- (2011) F. K. Knop et al. DIABETES OBESITY & METABOLISM
- Peripheral and Central GLP-1 Receptor Populations Mediate the Anorectic Effects of Peripherally Administered GLP-1 Receptor Agonists, Liraglutide and Exendin-4
- (2011) Scott E. Kanoski et al. ENDOCRINOLOGY
- Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide
- (2011) A Astrup et al. INTERNATIONAL JOURNAL OF OBESITY
- DURATION-5: Exenatide Once Weekly Resulted in Greater Improvements in Glycemic Control Compared with Exenatide Twice Daily in Patients with Type 2 Diabetes
- (2011) Thomas Blevins et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Defects in GLP-1 Response to an Oral Challenge Do Not Play a Significant Role in the Pathogenesis of Prediabetes
- (2011) Galina Smushkin et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Leptin receptor expression in hindbrain Glp-1 neurons regulates food intake and energy balance in mice
- (2011) Michael M. Scott et al. JOURNAL OF CLINICAL INVESTIGATION
- GLP-1 and energy balance: an integrated model of short-term and long-term control
- (2011) Jason G. Barrera et al. Nature Reviews Endocrinology
- Effects of Exenatide Combined with Lifestyle Modification in Patients with Type 2 Diabetes
- (2010) Caroline M. Apovian et al. AMERICAN JOURNAL OF MEDICINE
- Exenatide reduces food intake and activates the enteric nervous system of the gastrointestinal tract and the dorsal vagal complex of the hindbrain in the rat by a GLP-1 receptor
- (2010) Martha C. Washington et al. BRAIN RESEARCH
- PYY3-36 and Oxyntomodulin Can Be Additive in Their Effect on Food Intake in Overweight and Obese Humans
- (2010) B. C. T. Field et al. DIABETES
- Effects of Exenatide and Lifestyle Modification on Body Weight and Glucose Tolerance in Obese Subjects With and Without Pre-Diabetes
- (2010) J. Rosenstock et al. DIABETES CARE
- Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?
- (2010) M. A. Nauck et al. DIABETOLOGIA
- Arterial Destiffening With Weight Loss in Overweight and Obese Middle-Aged and Older Adults
- (2010) A. Laura Dengo et al. HYPERTENSION
- Hepatic-Portal Vein Infusions of Glucagon-Like Peptide-1 Reduce Meal Size and Increase c-Fos Expression in the Nucleus Tractus Solitarii, Area Postrema and Central Nucleus of the Amygdala in Rats
- (2010) I. Baumgartner et al. JOURNAL OF NEUROENDOCRINOLOGY
- Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial
- (2010) Michaela Diamant et al. LANCET
- Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial
- (2010) Richard M Bergenstal et al. LANCET
- Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial
- (2010) Richard E Pratley et al. LANCET
- Differential incretin effects of GIP and GLP-1 on gastric emptying, appetite, and insulin-glucose homeostasis
- (2010) T. Edholm et al. NEUROGASTROENTEROLOGY AND MOTILITY
- Obesity and leptin resistance: distinguishing cause from effect
- (2010) Martin G. Myers et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
- A Randomized Study on the Effect of Weight Loss on Obstructive Sleep Apnea Among Obese Patients With Type 2 DiabetesThe Sleep AHEAD StudyEffect of Weight Loss on Obstructive Sleep Apnea
- (2009) Gary D. Foster ARCHIVES OF INTERNAL MEDICINE
- Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)
- (2009) B. Zinman et al. DIABETES CARE
- Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
- (2009) M. Marre et al. DIABETIC MEDICINE
- Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial
- (2009) D. Russell-Jones et al. DIABETOLOGIA
- Gut Peptides: Targets for Antiobesity Drug Development?
- (2009) Timothy H. Moran et al. ENDOCRINOLOGY
- Molecular physiology of weight regulation in mice and humans
- (2009) R L Leibel INTERNATIONAL JOURNAL OF OBESITY
- Endogenous Glucagon-Like Peptide-1 Slows Gastric Emptying in Healthy Subjects, Attenuating Postprandial Glycemia
- (2009) Adam M. Deane et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Vagally mediated effects of glucagon-like peptide 1:in vitroandin vivogastric actions
- (2009) Gregory M. Holmes et al. JOURNAL OF PHYSIOLOGY-LONDON
- Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
- (2009) John B Buse et al. LANCET
- Association of Body Mass and Brain Activation during Gastric Distention: Implications for Obesity
- (2009) Dardo Tomasi et al. PLoS One
- Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug—naive patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, parallel-group study
- (2008) T MORETTO et al. CLINICAL THERAPEUTICS
- Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 study
- (2008) M. Nauck et al. DIABETES CARE
- Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes
- (2008) P. V. Højberg et al. DIABETOLOGIA
- Intrameal Hepatic Portal and Intraperitoneal Infusions of Glucagon-Like Peptide-1 Reduce Spontaneous Meal Size in the Rat via Different Mechanisms
- (2008) Elisabeth B. Rüttimann et al. ENDOCRINOLOGY
- Evidence that Intestinal Glucagon-Like Peptide-1 Plays a Physiological Role in Satiety
- (2008) Diana L. Williams et al. ENDOCRINOLOGY
- How strong is the association between abdominal obesity and the incidence of type 2 diabetes?
- (2008) N. Freemantle et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Crystal Structure of the Ligand-bound Glucagon-like Peptide-1 Receptor Extracellular Domain
- (2008) Steffen Runge et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Bariatric Surgery: Risks and Rewards
- (2008) Walter J. Pories JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study
- (2008) Guangwei Li et al. LANCET
- Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study
- (2008) Daniel J Drucker et al. LANCET
- Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial
- (2008) Alan Garber et al. LANCET
- The Obesity Epidemic: Pharmacological Challenges
- (2008) S. R. Bloom et al. MOLECULAR INTERVENTIONS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search